HER-2低表达乳腺癌的研究进展与未来展望
Research Progress and Future Prospect of HER-2 Low Expression Breast Cancer
摘要: 近年来对HER-2低表达乳腺的关注，在全球范围日益增加，随着新型靶向药物的研发及检测技术的发展，HER-2低表达乳腺癌与其他类型乳腺癌表现出不同的病理学及临床特征。对于HER-2低表达乳腺癌患者的预后，众多学者持有不同的观点尚无统一论据。本文阐述了近年来HER-2低表达乳腺癌的最新研究进展，重点介绍了HER-2低表达乳腺癌的生物学特性、目前病理实践中免疫组化判定HER-2低表达乳腺癌所遇到的问题，以及对这一新型领域未来的发展做一概述。
Abstract: In recent years, HER-2 low expression breast cancer has received increasing attention. With the development of new HER-2 targeted drugs and detection methods, HER-2 low breast cancer exhibit pathological and clinical features that differ from other types of breast cancer. For the prognosis of HER-2-low expression breast cancer, many scholars hold different views, and there is no unified ev-idence. In this paper, the latest research progress in breast cancer with low HER-2 expression in recent years is reviewed, focusing on the biological characteristics of HER-2 low breast cancer, and the problems encountered in the immunohistochemical detection of HER-2 low expression breast cancer in current pathological practice, and the future development of this new field is summarized.
文章引用：买吐鲁佰·米尔扎合买提, 卡吾力·居买, 地力木拉提·艾斯木吐拉, 李慧芳, 阿力清·阿不都萨拉木. HER-2低表达乳腺癌的研究进展与未来展望[J]. 临床医学进展, 2023, 13(10): 16593-16601. https://doi.org/10.12677/ACM.2023.13102323

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Schechter, A.L., Hung, M.C., et al. (1985) The Neu Gene: An erbB-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor. Science, 229, 976-978. [Google Scholar] [CrossRef] [PubMed]
[3] Xu, Y., Wang, Y., Gong, J., et al. (2021) Phase I Study of the Re-combinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate RC48-ADC in Patients with HER2-Positive Advanced Solid Tumors. Gastric Cancer, 24, 913-925. [Google Scholar] [CrossRef] [PubMed]
[4] Modi, S., Park, H., Murthy, R.K., et al. (2020) Antitumor Activ-ity and Safety of Trastuzumab Deruxtecan in Patients with HER-2-Low-Expressing Advanced Breast Cancer: Results from a Phase Ib Study. Journal of Clinical Oncology, 38, 1887-1896. [Google Scholar] [CrossRef] 
[5] Banerji, U., van Herpen, C.M.L., Saura, C., et al. (2019) Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER-2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study. The Lancet Oncology, 20, 1124-1135. [Google Scholar] [CrossRef] 
[6] Hanna, W.M. and Kwok, K. (2006) Chromogenic In-Situ Hybridization: A Viable Alternative to Fluorescence In-Situ Hybridization in the HER-2 Testing Algorithm. Modern Pa-thology, 19, 481-487. [Google Scholar] [CrossRef] [PubMed]
[7] 张瑰红, 施达仁, 梁晓曼, 等. 显色原位杂交和免疫组织化学检测乳腺癌HER-2/neu基因状况和蛋白表达的对照性研究[J]. 中华病理学杂志, 2006, 35(10): 580-583.
[8] 应建明, 郭蕾, 刘秀云, 等. 全自动银增强原位杂交检测乳腺癌患者人表皮生长因子受体2基因状态[J]. 中华医学杂志, 2010, 90(24): 1674-1677.
[9] 许燕, 杨文涛, 杨飞, 等. 双色银染原位杂交与荧光原位杂交在乳腺癌HER-2基因状态评估中的比较[J]. 中华病理学杂志, 2014, 43(4): 226-230.
[10] Wolff, A.C., Hammond, M.E.H., Allison, K.H., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122. [Google Scholar] [CrossRef] 
[11] Murthy, R.K., Loi, S., Okines, A., et al. (2020) Tucatinib, Trastuzumab, and Capecitabine for HER-2-Positive Metastatic Breast Cancer. The New England Jour-nal of Medicine, 382, 597-609. [Google Scholar] [CrossRef] 
[12] Tarantino, P., Hamilton, E., Tolaney, S.M., et al. (2020) HER-2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology, 38, 1951-1962. [Google Scholar] [CrossRef] 
[13] 刘月平, 薛卫成, 杨文涛, 步宏. 乳腺癌HER-2低表达病理检测进展及挑战[J]. 中华病理学杂志, 2022, 51(9): 799-802.
[14] 《乳腺癌HER-2检测指南(2019版)》编写组. 乳腺癌HER-2检测指南(2019版) [J]. 中华病理学杂志, 2019, 48(3): 169-175.
[15] Schalper, K.A., Kumar, S., Hui, P., et al. (2014) A Retrospective Population-Based Comparison of HER-2 Immunohistochemistry and Fluorescence in Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/College of American Pathologists Criteria. Archives of Pathology & Laboratory Medicine, 138, 213-219. [Google Scholar] [CrossRef] 
[16] Fernandez, A.I., Liu, M., Bellizzi, A., et al. (2022) Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology, 8, 607-614. [Google Scholar] [CrossRef] [PubMed]
[17] Schettini, F., Chic, N., Brasó-Maristany, F., et al. (2021) Clini-cal, Pathological, and PAM50 Gene Expression Features of HER-2-Low Breast Cancer. NPJ Breast Cancer, 7, 1. [Google Scholar] [CrossRef] [PubMed]
[18] Lim, S.K., Lee, M.H., Park, I.H., et al. (2016) Impact of Molec-ular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. Cancer Research and Treatment, 48, 133-141. [Google Scholar] [CrossRef] [PubMed]
[19] 白冰, 张艾佳, 郭新, 等. HER2低表达乳腺癌的临床病理特征和预后因素分析[J]. 中国医科大学学报, 2023, 52(6): 494-498.
[20] Prat, A., Bardia, A., Curigliano, G., et al. (2022) An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer without ERBB2 Amplification (HER2-Low). JAMA Oncology. [Google Scholar] [CrossRef] [PubMed]
[21] Denkert, C., Seither, F., Schneeweiss, A., et al. (2021) Clinical and Molecular Characteristics of HER-2-Low-Positive Breast Cancer: Pooled Analysis of Individual Patient Data from Four Prospective, Neoadjuvant Clinical Trials. The Lancet Oncology, 22, 1151-1161. [Google Scholar] [CrossRef] 
[22] Zhang, H., Katerji, H., Turner, B.M., et al. (2022) HER-2-Low Breast Cancers: Incidence, HER-2 Staining Patterns, Clinicopathologic Features, MammaPrint and Blue-Print Genomic Profiles. Modern Pathology, 35, 1075-1082. [Google Scholar] [CrossRef] [PubMed]
[23] Alves, F.R., Gil, L., Vasconcelos de Matos, L., et al. (2022) Im-pact of Human Epidermal Growth Factor Receptor 2 (HER-2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Cureus, 14, e22330. [Google Scholar] [CrossRef] [PubMed]
[24] Li, Y., Abudureheiyimu, N., Mo, H., et al. (2022) In Real Life, Low-Level HER-2 Expression May Be Associated with Better Outcome in HER-2-Negative Breast Cancer: A Study of the National Cancer Center, China. Frontiers in Oncology, 11, Article ID: 774577. [Google Scholar] [CrossRef] [PubMed]
[25] Gilcrease, M.Z., Woodward, W.A., Nicolas, M.M., et al. (2009) Even Low-Level HER-2 Expression May Be Associated with Worse Outcome in Node-Positive Breast Cancer. The American Journal of Surgical Pathology, 33, 759- 767. [Google Scholar] [CrossRef] 
[26] Agostinetto, E., Rediti, M., Fimereli, D., et al. (2021) HER-2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel), 13, Article No. 2824. [Google Scholar] [CrossRef] [PubMed]
[27] Fehrenbacher, L., Cecchini, R.S., Geyer, C.E., et al. (2020) NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy with or without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER-2 by FISH and with IHC 1+ or 2. Journal of Clinical Oncology, 38, 444-453. [Google Scholar] [CrossRef] 
[28] Ergun, Y., Ucar, G. and Akagunduz, B. (2023) Comparison of HER-2-Zero and HER-2-Low in Terms of Clinicopathological Factors and Survival in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis. Cancer Treatment Reviews, 115, Article ID: 102538. [Google Scholar] [CrossRef] [PubMed]
[29] Rossi, V., Sarotto, I., Maggiorotto, F., et al. (2012) Moderate Im-munohistochemical Expression of HER-2 (2+) without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. Oncologist, 17, 1418-1425. [Google Scholar] [CrossRef] [PubMed]
[30] Wang, J., Xu, B., Yuan, P., et al. (2014) HER-2 as a Predic-tive Factor for Successful Neoadjuvant Anthracycline Chemotherapy of Locally Advanced and Early Breast Cancer. The International Journal of Biological Markers, 29, e187- e192. [Google Scholar] [CrossRef] [PubMed]
[31] Pinhel, I., Hills, M., Drury, S., Salter, J., et al. (2012) ER and HER-2 Expression Are Positively Correlated in HER-2 Non-Overexpressing Breast Cancer. Breast Cancer Research, 14, R46. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, G., Ren, C., Li, C., et al. (2022) Distinct Clinical and Somatic Muta-tional Features of Breast Tumors with High-, Low-, or Non-Expressing Human Epidermal Growth Factor Receptor 2 Status. BMC Medicine, 20, Article No. 142. [Google Scholar] [CrossRef] [PubMed]
[33] Horisawa, N., Adachi, Y., Takatsuka, D., et al. (2022) The Frequency of Low HER-2 Expression in Breast Cancer and a Comparison of Prognosis between Patients with HER-2-Low and HER-2-Negative Breast Cancer by HR Status. Breast Cancer, 29, 234-241. [Google Scholar] [CrossRef] [PubMed]
[34] Pegram, M., Hsu, S., Lewis, G., et al. (1999) Inhibito-ry Effects of Combinations of HER-2/Neu Antibody and Chemotherapeutic Agents Used for Treatment of Human Breast Cancers. Oncogene, 18, 2241-2251. [Google Scholar] [CrossRef] [PubMed]
[35] Friess, T.S. and Bauer, A.M.B. (2002) In Vivo Activity of Recombi-nant Humanized Monoclonal Antibody 2C4 in Xenografts Is Independent of Tumor Type and Degree of HER-2 Over-expression. European Journal of Cancer, 38, S149. [Google Scholar] [CrossRef] 
[36] Gianni, L., Lladó, A., Bianchi, G., et al. (2010) Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epi-dermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 28, 1131-1137. [Google Scholar] [CrossRef] 
[37] Beck, A., Goetsch, L., Dumontet, C., et al. (2017) Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates. Nature Reviews Drug Discovery, 16, 315-337. [Google Scholar] [CrossRef] [PubMed]
[38] Ferraro, E., Drago, J.Z. and Modi, S. (2021) Implementing Anti-body-Drug Conjugates (ADCs) in HER-2-Positive Breast Cancer: State of the Art and Future Directions. Breast Cancer Research, 23, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[39] Burris, H.A., Tibbitts, J., Holden, S.N., et al. (2011) Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER-2+ Breast Cancer. Clinical Breast Cancer, 11, 275-282. [Google Scholar] [CrossRef] [PubMed]
[40] Verma, S., Miles, D., Gianni, L., et al. (2012) Trastuzumab Emtansine for HER-2-Positive Advanced Breast Cancer. The New England Journal of Medicine, 367, 1783-1791. [Google Scholar] [CrossRef] 
[41] Yver, A., Agatsuma, T. and Soria, J.C. (2020) The Art of Innovation: Clinical Development of Trastuzumab Deruxtecan and Redefining How Antibody-Drug Conjugates Target HER-2-Positive Cancers. Annals of Oncology, 31, 430- 434. [Google Scholar] [CrossRef] [PubMed]
[42] Sahin, U., Hartmann, F., Senter, P., Pohl, C., Engert, A., Diehl, V. and Pfreundschuh, M. (1990) Specific Activation of the Prodrug Mitomycin Phosphate by a Bispecific An-ti-CD30/Anti-Alkaline Phosphatase Monoclonal Antibody. Cancer Research, 50, 6944-6948.
[43] Tadokoro, J., Kakihata, K., Shimazaki, M., et al. (2011) Post-Marketing Surveillance (PMS) of All Patients Treated with Irinotecan in Japan: Clinical Experience and ADR Profile of 13,935 Patients. Japanese Journal of Clinical Oncology, 41, 1101-1111. [Google Scholar] [CrossRef] [PubMed]
[44] van der Lee, M.M., Groothuis, P.G., Ubink, R., et al. (2015) The Preclini-cal Profile of the Duocarmycin-Based HER-2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER-2-Expressing Breast Cancers. Molecular Cancer Therapeutics, 14, 692-703. [Google Scholar] [CrossRef] 
[45] Zhu, Y., Zhu, X., Wei, X., et al. (2021) HER-2-Targeted Therapies in Gastric Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188549. [Google Scholar] [CrossRef] [PubMed]
[46] Wang, J.Y., et al. (2021) RC48-ADC, a HER-2-Targeting Anti-body-Drug Conjugate, in Patients with HER-2-Positive and HER-2-Low Expressing Advanced or Metastatic Breast Cancer: A Pooled Analysis of Two Studies. Journal of Clinical Oncology, 39, 1022-1022. [Google Scholar] [CrossRef] 
[47] Shi, F., Liu, Y., Zhou, X., et al. (2022) Disitamab Ve-dotin: A Novel Antibody-Drug Conjugates for Cancer Therapy. Drug Delivery, 29, 1335-1344. [Google Scholar] [CrossRef] [PubMed]
[48] Le Joncour, V., Martins, A., Puhka, M., et al. (2019) A Novel Anti-HER-2 Antibody-Drug Conjugate XMT-1522 for HER-2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Molecular Cancer Therapeutics, 18, 1721-1730. [Google Scholar] [CrossRef] 
[49] Hamilton, E.P., et al. (2018) Phase 1 Dose Escalation of XMT-1522, a Novel HER-2-Targeting Antibody-Drug Conjugate (ADC), in Patients (pts) with HER-2-Expressing Breast, Lung and Gastric Tumors. Journal of Clinical Oncology, 36, 2546-2546.
[50] Modi, S., et al. (2019) A Phase III, Multicenter, Randomized, Open Label Trial of [fam-] Trastuzumab Deruxtecan (DS-8201a) versus Investigator’s Choice in HER-2-Low Breast Cancer. Journal of Clinical Oncology, 37, TPS1102. [Google Scholar] [CrossRef] 
[51] Bardia, A., et al. (2021) Trastuzumab Deruxtecan (T-DXd, DS-8201) vs Investigator’s Choice of Chemotherapy in Patients with Hormone Receptor-Positive (HR+), HER-2 Low Metastatic Breast Cancer Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting: A Randomized, Global Phase 3 Trial (DESTINY-Breast06). Cancer Research, 81, OT-03-09. [Google Scholar] [CrossRef] 
[52] 朱艺, 肖斌, 刘嘉慧, 等. Circ-0003910在HER-2阳性乳腺癌中的表达、定位、生物学作用及蛋白质组学研究[J]. 中国癌症杂志, 2022, 32(10): 979-989. [Google Scholar] [CrossRef] 
[53] Fehrenbacher, L., Cecchini, R.S., Geyer, C.E., et al. (2019) NSABP B-47/NRG Oncology Phase II Randomized Trial Comparing Adjuvant Chemotherapy with or without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER-2 by FISH and with IHC 1+ or 2.
[54] Xu, K., Bayani, J., Mallon, E., et al. (2022) Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer. The Journal of Molec-ular Diagnostics, 24, 775-783. [Google Scholar] [CrossRef] [PubMed]
[55] Hicks, D.G., Buscaglia, B., Goda, H., et al. (2018) A Novel Detection Methodology for HER-2 Protein Quantitation in Formalin-Fixed, Paraffin Embedded Clinical Samples Using Fluorescent Nanoparticles: An Analytical and Clinical Validation Study. BMC Can-cer, 18, Article No. 1266. [Google Scholar] [CrossRef] [PubMed]
[56] Harigopal, M., Barlow, W.E., Tedeschi, G., et al. (2010) Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows That both High and Low Levels of HER-2 Are Associated with Poor Outcome. The American Journal of Pathology, 176, 1639-1647. [Google Scholar] [CrossRef] [PubMed]
[57] Won, H.S., Ahn, J., Kim, Y., et al. (2022) Clinical Significance of HER-2-Low Expression in Early Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society. Breast Cancer Research, 24, Article No. 22. [Google Scholar] [CrossRef] [PubMed]

为你推荐